Test Price
2,800 AED✅ Home Collection Available
LAMA3 Gene Laryngo-Onycho-Cutaneous Syndrome (LOCS) Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين LAMA3 لمتلازمة الحنجرة-الظفر-الجلدية (LOCS) في الإمارات | 2800 درهم | إرشادات هيئة الصحة بدبي 2026
Clinical Excellence & Patient Safety Guarantee
- 99.9% Diagnostic Sensitivity – Next-Generation Sequencing (NGS) validated under ISO 9001:2015 Certified Laboratory (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics – Paid Hospital-Grade Home Collection via ISO-Certified Cold-Chain, including VIP Mobile Phlebotomy (8 AM–11 PM).
- Telephonic Post-Test Clinical Guidance – Board-certified physician interpretation session included to clarify result implications.
- Direct Insurance Billing Verification via WhatsApp +971 54 548 8731.
ملخص تنفيذي: يقدم هذا الفحص الجيني المتقدم تحليلًا شاملاً لجين LAMA3 باستخدام تقنية التسلسل من الجيل التالي (NGS) بدقة تشخيصية تبلغ 99.9%، معتمدًا من هيئة الصحة بدبي وفقًا للمرسوم بقانون اتحادي رقم 41 لسنة 2024 وقانون حماية البيانات الشخصية الإماراتي، لضمان تشخيص متلازمة الحنجرة-الظفر-الجلدية النادرة وتوجيه خطة المراقبة السريرية.
Clinical Overview & Diagnostic Precision
This advanced genetic test analyzes the LAMA3 gene via Next-Generation Sequencing (NGS) to definitively diagnose Laryngo-Onycho-Cutaneous Syndrome (LOCS), a rare autosomal recessive genodermatosis characterized by skin fragility, nail dystrophy, laryngeal granulation tissue, and a significantly elevated risk of squamous cell carcinoma. يكشف الاختبار عن الطفرات المسببة للمرض في جين LAMA3، مما يتيح تشخيصًا دقيقًا وفحصًا عائليًا مبكرًا ووضع خطة مراقبة للسرطان.
| Parameter | Our NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | 99.9% analytical sensitivity / specificity | Limited to pre‑targeted variants; ~95% |
| Methodology | NGS (full‑gene coverage with CNV detection) | Sanger (exon‑by‑exon, slow) |
| Speed | 3–4 weeks | 8–12 weeks |
Physician Insight & Safety Protocol
“As a dermatogenetic physician, I understand the distress a suspected diagnosis of Laryngo-Onycho-Cutaneous Syndrome can bring. This NGS test provides the molecular certainty needed to tailor surveillance and protect family members, yet it must always be correlated with your complete clinical picture. I urge you not to view the result in isolation.”
— Dr. PRABHAKAR REDDY, DHA License No. 61713011
Medication Warning: Do not discontinue any prescribed medication or topical treatment without direct consultation with your supervising physician. Genetic results do not replace ongoing dermatological or oncological care.
Exclusion Criteria & Emergency Red Flags
- Sample rejection: DNA samples with severe degradation, insufficient quantity, or known hematopoietic neoplasm contamination (potential somatic mosaicism confound).
- Not indicated for: Somatic (acquired) variants in tumour tissue; this is a germline constitutional test.
- Seek Emergency Care if you experience sudden stridor, hoarseness with dyspnoea, or rapid airway compromise – all potential signs of acute laryngeal granulation worsening in LOCS.
Patient FAQ & Clinical Guidance
What does the LAMA3 genetic test detect?
This test identifies pathogenic mutations in the LAMA3 gene that cause Laryngo-Onycho-Cutaneous Syndrome, enabling accurate diagnosis, family screening, and cancer surveillance planning. The NGS approach sequences all coding exons and flanking intronic regions, detecting small variants, deletions, and duplications that would be missed by targeted methods.
يحدد هذا الاختبار الطفرات المرضية في جين LAMA3 المسببة لمتلازمة الحنجرة-الظفر-الجلدية، مما يسمح بتشخيص دقيق وفحص أفراد العائلة ووضع خطة مراقبة الأورام السرطانية.
How is the test performed and what sample is needed?
A simple peripheral blood draw, extracted DNA, or a single drop of blood on an FTA card can be collected via a hospital‑grade home visit. The sample is transported in ISO‑certified cold‑chain conditions to our 2026 DHA‑compliant genomics laboratory, where DNA is extracted, libraries are prepared, and NGS is performed with bioinformatic analysis.
يتم جمع عينة دم بسيطة أو الحمض النووي المستخلص أو قطرة دم على بطاقة FTA خلال زيارة منزلية معتمدة، ثم تُنقل وفق سلسلة تبريد معتمدة إلى مختبرنا الجيني وفق معايير هيئة الصحة بدبي.
Are there any special preparations or legal considerations?
No fasting or medication adjustments are required. However, a pre‑ genetic counselling session is mandatory to draw a pedigree of affected family members and obtain informed consent, in strict compliance with UAE Federal Decree‑Law No. 41 of 2024 (Art. 87) on genetic privacy, the 2026 CDS Law protecting minors, and UAE PDPL. All data is anonymised and stored on secure UAE‑based servers.
لا يشترط الصيام أو تغيير الأدوية، لكن جلسة استشارة وراثية قبل الفحص إلزامية لرسم شجرة العائلة والحصول على موافقة مستنيرة وفقًا للمرسوم بقانون اتحادي رقم 41 لسنة 2024 وقانون حماية البيانات الشخصية.
UAE Regulatory Compliance
- Federal Decree-Law No. 41 of 2024 on Genetic Data, Article 87 — protects confidentiality and mandates informed consent.
- CDS Law 2026 (Minors) — genetic testing for individuals under 18 years requires parental consent and clinical necessity.
- UAE Personal Data Protection Law (PDPL) — ensures de‑identification and secure storage.
ISO 9001:2015 Certified Facility | Cert: INT/EGQ/2509DA/3139 | DHA Facility License 9834453 | WhatsApp Support: +971 54 548 8731
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians